• Fireside chat will be held on Monday, April 17, 2023, at 11:00 a.m. ET

NEW HAVEN, Conn., April 11, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced that Jennifer Good, President and Chief Executive Officer, Lisa Delfini, Chief Financial Officer, and David Clark, MD, Chief Medical Officer, will be participating in a fireside chat at the 22^nd Annual Needham Virtual Healthcare Conference on Monday, April 17, at 11:00 a.m. ET. Ms. Good and Ms. Delfini will also participate in investor meetings with attendees.

A live webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing Haduvio, an investigational therapy in an oral extended-release formulation of nalbuphine, for the treatment of chronic cough in IPF and other chronic cough indications. Haduvio is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that works both centrally and peripherally. The ĸ and µ receptors are known critical mediators of cough. Parenteral nalbuphine has been approved and marketed for over 20 years for the treatment of acute pain indications and is not scheduled by the DEA in the United States or by regulatory authorities in most of Europe. Trevi intends to propose Haduvio as the trade name for nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.

For more information, visit www.TreviTherapeutics.com and follow the Company on Twitter and LinkedIn.

Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
Rosalia Scampoli
914-815-1465
This email address is being protected from spambots. You need JavaScript enabled to view it.